FDA postpones panel for Glaxo's COPD drug as snowstorm advances
March 5 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has postponed a meeting of outside advisers scheduled for March 7 to review a drug developed by GlaxoSmithKline Plc and Theravance Inc for chronic obstructive pulmonary disease (COPD).
The agency did not officially give a reason for the postponement but it comes as a major snowstorm bears down on the Northeastern United States, including Washington D.C., where the panelists were due to meet.
The agency said it would post briefing materials related to the drug, to be called Breo if approved in the United States, no later than two days before the next meeting, once announced.
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters press on |
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Singapore hit by rare outbreak of rioting, 27 arrested |
- Venezuela's Maduro to raise pressure on business after local vote